PREPARATION AND INVITRO EVALUATION OF SLOW RELEASE KETOPROFEN MICROCAPSULES FORMULATED INTO TABLETS AND CAPSULES

被引：13

作者：

ELKHODAIRY, KA

ESHRA, AG

NADA, AH

MORTADA, SAM

机构：

[1] Department of Industrial Pharmacy, Faculty of Pharmacy Alexandria University, Alexandria

[2] Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria

来源：

JOURNAL OF MICROENCAPSULATION | 1992年 / 9卷 / 03期

关键词：

D O I：

10.3109/02652049209021251

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

Ketoprofen powder was encapsulated with Eudragit RL/RS polymer solutions in isopropanol-acetone 1:1, using a simple and rapid method. Microcapsules were prepared using Eudragit solutions with different RL/RS ratios. The encapsulation process produces free-flowing microcapsules with good drug content and marked decrease in dissolution rate. The retardation in release profile of ketoprofen from microcapsules was a function of the polymer ratio employed in the encapsulation process. In vitro release of ketoprofen from microcapsules either filled in gelatin capsules or compressed into tablets, using calcium sulphate as diluent, confirmed the efficiency of the encapsulation process for preparing prolonged release medication. A capsule formulation with optimum sustained-release profile was suggested.

引用

页码：365 / 373

页数：9

共 18 条

[1] Bianchini R., Vecchio C., Modified release bead coated with cellulose derivatives by the pan coating technique, Bolletina Chimico Farmaceutica, 126, pp. 441-446, (1987)
[2] Cakiryildiz C., Mehta P.J., Rahmen W., Schoenleber D., Dissolution studies with a multichannel continuous-flow apparatus, Journal of Pharmaceutical Science, 64, pp. 1692-1695, (1975)
[3] Del Favero A., Antiinflammatory analgesics and drugs used in rheumatoid arthritis and gout, Side Effects of Drugs, (1988)
[4] Hagen K.J., New development in delayed-release delivery, Chemist and Druggist, 218, (1982)
[5] Houghton G.W., Dennis M.J., Rigler E.D., Parsons R.L., Comparative pharmacokinetics of ketoprofen derived from single oral dose of ketoprofen capsules, Biopharmacology of Drug Disposition, 5, pp. 203-209, (1984)
[6] Houghton G.W., Dennis M.J., Templeton R., Calver R.M., Cresswell D.G., Pharmacokinetic study of retarded dose of a new controlled release form of ketoprofen (Oruvail), International Journal of Clinical Pharmacology and Therapeutic Toxicology, 22, pp. 1131-1132, (1984)
[7] Houghton G.W., Dennis M.J., Rigler E.D., Parsons R.L., Urinary pharmacokinetics of orally administered ketoprofen in man, European Journal of Drug Metabolism and Pharmacokinetics, 9, pp. 201-204, (1984)
[8] Kitamori N., Makino T., Effect of drug content and drug particle size during compression, Journal of Pharmacy and Pharmacology, 31, pp. 501-507, (1979)
[9] Lang B., vitro release rate as a standard requirement, Pharmazie, 26, pp. 661-664, (1971)
[10] Marcolongo R., Rubegni M., Prouvedi D., Double blind, interpatient comparison of plain and slow release ketoprofen in Osteoarthritis, International Journal of Clinical Pharmacology and Therapeutic Toxicology, 22, pp. 337-381, (1981)

← 1 2 →